Literature DB >> 12239142

Immunophenotypic clustering of myelodysplastic syndromes.

Marc Maynadié1, Françoise Picard, Bernard Husson, Bernard Chatelain, Yvan Cornet, Geneviève Le Roux, Lydia Campos, Alex Dromelet, Pascalle Lepelley, Hélène Jouault, Michèle Imbert, Michelle Rosenwadj, Véronique Vergé, Philippe Bissières, Martine Raphaël, Marie Christine Béné, Jean Feuillard.   

Abstract

Myelodysplastic syndromes (MDSs) are heterogeneous diseases of bone marrow (BM) cell precursors for which immunophenotypic characterization is still considered irrelevant despite the accuracy and sensitivity of flow cytometry techniques. The aim of this study was to determine whether immunophenotypic abnormalities could be defined in MDSs and could correlate with the French-American-British classification and cytogenetics. Analysis was performed on 275 BM samples (207 MDS patients, 68 controls) and 25 control blood samples. Immunophenotyping was based on a primary gating of blast cells, monocytes, and granulocytes according to CD45 antigen expression and side scatter light diffraction. Immunophenotypic hierarchical clustering was performed to analyze the results. The data obtained show that (1) immunophenotypic clustering partly discriminates patients with refractory anemia with excess blasts/refractory anemia with excess blasts in transformation (RAEB/RAEB-T), chronic myelomonocytic leukemia (CMML), and refractory anemia/refractory anemia with ring sideroblasts (RA/RARS) for CD45(lo) blast cells and patients with RA/CMML, RARS, and RAEB/RAEB-T for CD45(hi)/side scatter(hi) (SS(hi)) granulocytes; (2) the most discriminating markers were CD16, CD34, CD36, CD38, CD71, and HLA-DR for blast cells and CD11b, CD13, CD33, CD36, CD38, CD71, and HLA-DR for CD45(hi)/SS(hi) granulocytes; (3) clusters related to CD34 expression were associated with high levels of blast cells on BM smear; (4) clusters related to high levels of CD36 expression on CD45(lo) blast cells and CD45(hi)/SS(hi) granulocytes were associated with a poor International Prognosis Scoring System score; and (5) high levels of CD71 expression on CD45(hi)/SS(hi) granulocytes were associated with the RARS category. These results show a close relationship between immunophenotypic abnormalities and BM dysplasia and suggest that flow cytometry could be a future tool for the characterization of MDSs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239142     DOI: 10.1182/blood-2002-01-0230

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Cytomics, the human cytome project and systems biology: top-down resolution of the molecular biocomplexity of organisms by single cell analysis.

Authors:  G Valet
Journal:  Cell Prolif       Date:  2005-08       Impact factor: 6.831

2.  Identification of CD13+CD36+ cells as a common progenitor for erythroid and myeloid lineages in human bone marrow.

Authors:  Ling Chen; Zhigang Gao; Jianqiong Zhu; Griffin P Rodgers
Journal:  Exp Hematol       Date:  2007-07       Impact factor: 3.084

3.  Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

4.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Authors:  Peter L Greenberg; Zhuoxin Sun; Kenneth B Miller; John M Bennett; Martin S Tallman; Gordon Dewald; Elisabeth Paietta; Richard van der Jagt; Jessie Houston; Mary L Thomas; David Cella; Jacob M Rowe
Journal:  Blood       Date:  2009-06-29       Impact factor: 22.113

5.  Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.

Authors:  Uta Oelschlaegel; Theresia M Westers; Brigitte Mohr; Michael Kramer; Stefani Parmentier; Katja Sockel; Christian Thiede; Martin Bornhäuser; Gerhard Ehninger; Arjan A van de Loosdrecht; Uwe Platzbecker
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

6.  Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Valérie Bardet; Orianne Wagner-Ballon; Julien Guy; Céline Morvan; Camille Debord; Franck Trimoreau; Emmanuel Benayoun; Nicolas Chapuis; Nicolas Freynet; Cédric Rossi; Stéphanie Mathis; Marie-Pierre Gourin; Andréa Toma; Marie C Béné; Jean Feuillard; Estelle Guérin
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

Review 7.  Data analysis in flow cytometry: the future just started.

Authors:  Enrico Lugli; Mario Roederer; Andrea Cossarizza
Journal:  Cytometry A       Date:  2010-07       Impact factor: 4.355

Review 8.  Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Authors:  Anna Porwit
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

9.  Flow cytometric immunophenotyping: emerging as an important diagnostic tool in the evaluation of cytopenic patients.

Authors:  Maryalice Stetler-Stevenson
Journal:  Leuk Res       Date:  2009-03-26       Impact factor: 3.156

10.  A survey of flow cytometry data analysis methods.

Authors:  Ali Bashashati; Ryan R Brinkman
Journal:  Adv Bioinformatics       Date:  2009-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.